Robert Gyurko

Robert Gyurko

Auto-generated profile, based on publicly available information

Robert Gyurko

Department of Periodontology and Oral Biology Goldman School of Dental Medicine Boston University Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
PKPeter J. Kuhlencordt
Peter J. Kuhlencordt
RGRobert Gyurko
Robert Gyurko
FHFred Han
Fred Han
MSMarielle Scherrer-Crosbie
Marielle Scherrer-Crosbie
TAThomas H. Aretz
Thomas H. Aretz
PHPaul Huang
Paul Huang
Background To test whether deficiency in endothelial nitric oxide synthase (eNOS) affects atherosclerosis development, we compared lesion formation in apolipoprotein E (apoE)/eNOS-double knockout (DKO) and apoE-knockout (KO) control animals. Methods and Results After 16 weeks of “Western-type” diet, apoE/eNOS-DKO males and females showed significant increases in lesion area of 93.6% and 59.2% compared with apoE-KO mice. All apoE/eNOS-DKO animals studied developed peripheral coronary arteriosclerosis, associated with perivascular and myocardial fibrosis, whereas none of the apoE-KO mice did. Transthoracic echocardiography showed a significantly increased left ventricular wall thickness and decreased fractional shortening in DKO animals. Mean arterial pressure was increased in DKO mice and was comparable in degree to eNOS-KO animals. Male DKO animals developed atherosclerotic abdominal aneurysms and aortic dissection. Conclusions eNOS deficiency increases atherosclerosis in Western-type diet-fed apoE-KO animals and introduces coronary disease and an array of cardiovascular complications, including spontaneous aortic aneurysm and dissection. This phenotype constitutes the first murine model to demonstrate distal coronary arteriosclerosis associated with evidence of myocardial ischemia, infarction, and heart failure. Hypertrophy and reduced left ventricular function cannot be explained by increased blood pressure alone, because eNOS-KO animals do not develop these complications.

11 June 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
JCJiqiu Chen
Jiqiu Chen
CTChing Tung
Ching Tung
UMUmar Mahmood
Umar Mahmood
VNVasilis Ntziachristos
Vasilis Ntziachristos
RGRobert Gyurko
Robert Gyurko
RWRalph Weissleder
Ralph Weissleder
Background — Atherosclerotic plaque rupture, the most important cause of acute cardiovascular incidents, has been strongly associated with vascular inflammation. On the basis of the hypothesis that the inflammatory response and proteolysis lead to plaque rupture, we have examined the role of cathepsin B as a model proteolytic enzyme. Methods and Results — Using western-type diet–fed apoE and apoE/endothelial NO synthase double knockout mice as models of atherosclerosis, we show (1) that cathepsin B is upregulated in atherosclerotic lesions characterized by high degrees of inflammation compared with normal aorta or silent lesions,(2) that intravenously injectable novel cathepsin B imaging beacons are highly activated within active atherosclerotic lesions and colocalize with cathepsin B immunoreactivity, and(3) that cathepsin B activity in atherosclerotic lesions can be imaged in whole animals by using a novel near-infrared tomographic imaging system. Conclusions — These studies indicate that cathepsin B, and potentially other proteases, may serve as a biomarker for vulnerable plaques when probed with beacons. The tomographic in vivo imaging method as well as catheter-based optical sensing methods could be readily adapted to screening and potentially to the molecular profiling of a number of proteases in vulnerable plaque in vivo.

1 December 1993 in Regulatory Peptides
Verified
Journal Article
Closed access
RGRobert Gyurko
Robert Gyurko
DWDonna Wielbo
Donna Wielbo
MPM. Ian Phillips
M. Ian Phillips

10 March 2011 in Genes & Immunity
Verified
Journal Article
Closed access
BNBarbara S Nikolajczyk
Barbara S Nikolajczyk
MJM Jagannathan-Bogdan
M Jagannathan-Bogdan
HSH Shin
H Shin
RGR Gyurko
R Gyurko

13 November 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
JCJiqiu Chen
Jiqiu Chen
PKPeter J. Kuhlencordt
Peter J. Kuhlencordt
JAJoshua Astern
Joshua Astern
RGRobert Gyurko
Robert Gyurko
PHPaul Huang
Paul Huang
Background Apolipoprotein E (apoE)/endothelial nitric oxide synthase (eNOS) double knockout (DKO) mice demonstrate accelerated atherosclerosis and develop abdominal aortic aneurysms and aortic dissection, suggesting a role for eNOS in suppressing atherogenesis. To test whether accelerated atherosclerosis and aortic aneurysms were due to hypertension, we administered hydralazine to male apoE/eNOS DKO mice to reduce blood pressure. Methods and Results Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a dose that lowers the blood pressure to levels seen in apoE KO mice. The mice were fed a Western-type diet for 16 weeks, and lesion formation was assessed by inspection of the vessel and staining with Sudan IV. Hydralazine-treated, normotensive male apoE/eNOS DKO mice developed increased aortic lesion areas (30.0±2.8%, n=11) compared with male apoE KO mice (14.6±0.8%, n=7). The extent of lesion formation was not significantly different from male apoE/eNOS DKO mice that were not given hydralazine (28.3±3.1%, n=9). Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed abdominal aortic aneurysms. Conclusions Hypertension is not required for the accelerated atherosclerosis seen in apoE/eNOS DKO animals, and control of hypertension during a 16-week period does not prevent aortic aneurysm formation.

15 January 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LGLi Gao
Li Gao
DFDan Faibish
Dan Faibish
GFGabrielle Fredman
Gabrielle Fredman
BHBruno S Herrera
Bruno S Herrera
NCNan Chiang
Nan Chiang
RGRobert Gyurko
Robert Gyurko
The polyunsaturated ω-3 fatty acid eicosapentaenoic acid–derived resolvin E1 (RvE1) enhances resolution of inflammation, prevents bone loss, and induces bone regeneration. Although the inflammation-resolving actions of RvE1 are characterized, the molecular mechanism of its bone-protective actions are of interest. To test the hypothesis that receptor-mediated events impact bone changes, we prepared transgenic mice overexpressing the RvE1 receptor chemokine-like receptor 1 (chemR23) on leukocytes. In zymosan-initiated peritonitis, neutrophil polymorphonuclear leukocyte infiltration in response to RvE1 was limited requiring log order lower doses in chemR23tg mice. Ligature-induced alveolar bone loss was diminished in chemR23tg mice. Local RvE1 treatment of uniform craniotomy in the parietal bone significantly accelerated regeneration of the bone defect. In in vitro bone cultures, RvE1 significantly enhanced expression of osteoprotegerin (OPG) without inducing change in receptor activator of NF-κB ligand levels, whereas the osteogenic markers alkaline phosphatase, bone sialoprotein, and Runt-related transcription factor 2 remained unchanged. These results indicate that RvE1 modulates osteoclast differentiation and bone remodeling by direct actions on bone, rescuing OPG production and restoring a favorable receptor activator of NF-κB ligand/OPG ratio, in addition to known anti-inflammatory and proresolving actions.